These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 17559743

  • 1. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G.
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB, Greiner JV.
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study.
    Finegold I, Granet DB, D'Arienzo PA, Epstein AB.
    Clin Ther; 2006 Oct; 28(10):1630-8. PubMed ID: 17157118
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [Abstract] [Full Text] [Related]

  • 7. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC.
    Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
    Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ.
    Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS.
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H, Ohashi Y, Takamura E.
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL, Abelson MB, Ober A, Gotnes PJ.
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
    Butrus S, Greiner JV, Discepola M, Finegold I.
    Clin Ther; 2000 Dec; 22(12):1462-72. PubMed ID: 11192137
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
    Brodsky M, Berger WE, Butrus S, Epstein AB, Irkec M.
    Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
    [Abstract] [Full Text] [Related]

  • 17. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI, Kennedy KS, Gow JA, Torkildsen GL, Abelson MB, Gomes PJ, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Study Group.
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM, Tekelioglu Y, Turk A, Akyol N.
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of olopatadine versus epinastine for treating allergic conjunctivitis caused by Japanese cedar pollen: a double-blind randomized controlled trial.
    Fukushima A, Ebihara N.
    Adv Ther; 2014 Oct; 31(10):1045-58. PubMed ID: 25269854
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
    Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ.
    Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.